Arvinas (ARVN)
(Delayed Data from NSDQ)
$31.44 USD
-0.51 (-1.60%)
Updated May 10, 2024 04:00 PM ET
After-Market: $31.46 +0.02 (0.06%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARVN 31.44 -0.51(-1.60%)
Will ARVN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ARVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARVN
Acadia (ACHC), Geisinger JV Begin Construction of New Hospital
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
ARVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
Why Earnings Season Could Be Great for Arvinas (ARVN)
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
Other News for ARVN
Cantor picks 14 undervalued biotech stocks worth a second look
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
Arvinas price target lowered by $3 at Wells Fargo, here's why
Buy Rating Affirmed on Arvinas with Promising Trial Updates and Robust Financial Outlook
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Arvinas Holding Company (ARVN) and uniQure (QURE)